Thalidomide in treatment of connective diseases and vasculities;La talidomide nel trattamento delle connettiviti e delle vasculiti

Reumatismo

Volumn 58, Issue 3, 2006, Pages 187-190

  Maruotti, N ^a   Cantatore, F P ^a   Ribatti, D ^b,c  

^a UNIVERSITY OF FOGGIA   (Italy)

^b UNIVERSITY OF BARI   (Italy)

^c POLICLINICO   (Italy)

Author keywords

Beh et's disease; Systemic lupus erythematosus; Thalidomide

Indexed keywords

CELL ADHESION MOLECULE; FIBROBLAST GROWTH FACTOR 2; GAMMA INTERFERON; INTEGRIN RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANGIOGENESIS; BEHCET DISEASE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CONNECTIVE TISSUE DISEASE; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; HELPER CELL; HUMAN; LEUKOCYTE MIGRATION; NATURAL KILLER T CELL; NEUTROPHIL CHEMOTAXIS; REVIEW; SKIN DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; VASCULITIS;

ADMINISTRATION, ORAL; ANGIOGENESIS INHIBITORS; BEHCET SYNDROME; CONTROLLED CLINICAL TRIALS; CONTROLLED CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; PATIENT SELECTION; REMISSION INDUCTION; THALIDOMIDE; TIME FACTORS;

EID: 33749025817     PISSN: 00487449     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Lenz W. A personal perspective on the thalidomide tragedy. Teratology 1992; 46: 417-18.
2. D'Amato RJ. Thalidomide: An Antineoplastic Agent. Current Oncology Reports 2002; 4: 56-62.
3. Barnhill R, McDougall AC. Thalidomide: use and possible mode of action in reactional lepromatous leprosy and in various other conditions. J Am Acad Dermatol 1982; 7: 317-23.
4. Bernal JE, Duran MM, Londono F, Umana A. Cellular immune effects of thalidomide in actinic prurigo. Int J Dermatol 1992; 31: 599-600.
5. Guillaume JC, Moulin G, Dieng MT, Thierno DM. Crossover study of thalidomide vs placebo in Jessner's lymphocytic infiltration of the skin. Arch Dermatol 1995; 131: 1032-5.
6. Moraes M, Russo G. Thalidomide and Its Dermatologic Uses. Am J Med Sci 2001; 321: 321-6.
7. Gad SM, Shannon EJ, Krotoski WA, Hastings RC. Thalidomide induces imbalances in T-lymphocyte subpopulations in the circulating blood of healthy males. Lepr Rev 1985; 56: 35-9.
8. Haslett PA, Corral LG, Albert M, Kaplan G. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med 1998; 187: 1885-92.
9. von Moos R, Stolz R, Cerny T, Gillessen S. Thalidomide: from tragedy to promise. Swiss Med Wkly 2003; 133: 77-87.
10. Ribatti D, Vacca A. Therapeutic renaissance of thalidomide in the treatment of haematological malignancies; Leukemia 2005; 19: 1525-31.
11. Keenan RJ, Eiras G, Burckart GJ, Stuart RS, Hardesty RL, Vogelsang G, et al. Immunosuppressive properties of thalidomide. Inhibition of in vitro lymphocyte proliferation alone and in combination with cyclosporine or FK506. Transplantation 1991; 52: 908-10.
12. Thomas DA, Kantarjian HM. Current role of thalidomide in cancer treatment. Curr Opin Oncol 2000; 12: 564-73.
13. Hideshima T, Chauhan D, Shima Y, Raje N, Davies FE, Tai YT, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000; 96: 2943-50.
14. Turk BE, Jiang H, Liu JO. Binding of thalidomide to alpha1-acid glycoprotein may be involved in its inhibitory action on tumor necrosis factor production. Proc Natl Acad Sci USA 1996; 93: 7552-6.
15. Moller DR, Wysocka M, Greenlee BM, Ma X, Wahl L, Flockhart DA, et al. Inhibition of IL-12 production by thalidomide. J Immunol 1997; 159: 5157-61.
16. Moreira AL, Corral LG, Ye W, Johnson B, Stirling D, Muller GW, et al. Thalidomide and thalidomide analogs reduce HIV type 1 receptor replication in human macrophages in vitro. AIDS Res Hum Retrov 1997; 10: 857-63.
17. Rowland TL, Mc Hugh SM, Deighton J, Dearman RJ, Ewan PW, Kimber I. Differential regulation by thalidomide and dexamethasone of cytokine expression in human peripheral blood mononuclear cells. Immunopharmacology 1998; 40: 11-20.
18. Calderon P, Anzilotti M, Phelps R. Thalidomide in dermatology. New indications for an old drug. Int J Dermatol 1997; 36: 881-6.
19. Shannon EJ, Sandoval F. Thalidomide increases the synthesis of IL-2 in cultures of human mononuclear cells stimulated with concanavalin-A, staphylococcal enterotoxin A, and purified protein derivative. Immunopharmacology 1995; 31: 109-16.
20. Partida-Sanchez S, Favila-Castillo L, Pedraza-Sanchez S, Gomez-Melga M, Saul A, Estrada-Parra S, et al. IgG antibody subclasses, tumor necrosis factor and IFN-gamma levels in patients with type II lepra reaction on thalidomide treatment. Int Arch Allergy Immunol 1998; 116: 60-6.
21. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994; 91: 4082-5.
22. Versapuech J, Beylot-Barry M, Doutre MS, Beylot C. Subacute cutaneous lupus. Evolutive and therapeutic features of a series of 24 cases. Presse Med 2000; 29: 1596-9.
23. Sato EI, Assis LS, Lourenzi VP, Andrade LE. Long-term thalidomide use in refractory cutaneous lesions of systemic lupus erythematosus. Rev Assoc Med Bras 1998; 44: 289-93.
24. Atra E, Sato EI. Treatment of the cutaneous lesions of systemic lupus erythematosus with thalidomide. Clin Exp Rheumatol 1993; 11: 487-93.
25. Duong DJ, Spigel GT, Moxley RT, Gaspari AA. American experience with low-dose thalidomide therapy for severe cutaneous lupus erythematosus. Arch Dermatol 1999; 135: 1079-87.
26. Brik R, Shamali H, Bergman R. Successful Thalidomide Treatment of Severe Infantile Behçet Disease. Pediatric Dermatology 2001; 18: 143.
27. Hamuryudan V, Mat C, Saip S, Ozyazgan Y, Siva A, Yurdakul S, et al. Thalidomide in the Treatment of the Mucocutaneous Lesions of the Behcet Syndrome. Ann Intern Med 1998; 128: 443-50.